Synthesis of Anticancer HDAC Inhibitor Natural Products and Analogs

Information

  • Research Project
  • 7980680
  • ApplicationId
    7980680
  • Core Project Number
    R15CA152869
  • Full Project Number
    1R15CA152869-01
  • Serial Number
    152869
  • FOA Number
    PA-06-042
  • Sub Project Id
  • Project Start Date
    6/16/2010 - 14 years ago
  • Project End Date
    6/15/2014 - 10 years ago
  • Program Officer Name
    LEES, ROBERT G.
  • Budget Start Date
    6/16/2010 - 14 years ago
  • Budget End Date
    6/15/2014 - 10 years ago
  • Fiscal Year
    2010
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/16/2010 - 14 years ago
Organizations

Synthesis of Anticancer HDAC Inhibitor Natural Products and Analogs

DESCRIPTION (provided by applicant): This research program targets the synthesis of anticancer chemotherapeutics that are based on a class of natural product that inhibit histone deacetylase, which is a protein partly responsible for carcinogenesis. The proposed approach represents the first potential solid- phase method for generating the natural products in this class, one of which is already in phase II clinical trials for cancer treatment. Because it will ultimately be carried out on the solid-phase, the route described herein will provide fast, efficient access to a host of analogs (compounds similar to the natural products) that have not been available through any other reported synthetic approaches. Such analogs are expected to be a rich source of potential anticancer chemotherapeutics, and also embody a host of new structures for the study of how these molecules interact with their biological target proteins. Specifically, the outcomes of the proposed work include (1) a synthetic strategy for constructing two potential anticancer natural products;(2) a generally applicable protocol, based on this new synthetic strategy, for synthesizing not only the natural products, but a wider range of similar compounds than is currently available by any other established route towards such molecules;and (3) the synthesis of potential anticancer analogs of the natural products. The new synthetic methodology will provide access not only to the natural products, but to analogs containing components that have demonstrated importance for their biological activity. Using the methods proposed here, potential chemotherapeutics based on the target class of natural products will for the first time be accessible containing combinations of the best features of the most effective compounds previously reported. Moreover, this extremely flexible synthetic approach will also permit the construction of more creative, varied potential therapeutics than any established routes allow. Additionally, the proposed strategy will be particularly conducive to producing new compounds quickly, efficiently, and in parallel. Ultimately, large numbers of such compounds will therefore be accessible. Aside from leading to the next generation of potential anticancer therapeutics, along with the strategy to make countless others, this research program aims to educate and inspire the next generation of undergraduate students to enter scientific and health-related fields. PUBLIC HEALTH RELEVANCE: The major goal of the proposed work is the synthesis of a host of potential anticancer chemotherapeutics structurally similar to natural products that inhibit a protein partly responsible for carcinogenesis. The strategy used to assemble these molecules is significantly different from any other currently established method, and holds the promise of generating possible drug candidates that other methods have not been able to generate. In addition to providing new kinds of compounds, the proposed strategy will also be able to produce drug candidates more quickly than any other reported method.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R15
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    355523
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NCI:355523\
  • Funding Mechanism
    Research Projects
  • Study Section
    DMP
  • Study Section Name
    Drug Discovery and Molecular Pharmacology Study Section
  • Organization Name
    HOBART AND WILLIAM SMITH COLLEGES
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    079680203
  • Organization City
    GENEVA
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    144563304
  • Organization District
    UNITED STATES